Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pertuzumab

Roche Basel Switzerland

Roche cites COVID-19 and biosimilars in Q2 decline

Pharmaceutical sales took a 4% hit in Swiss francs

- PMLiVE

NICE recommends Astellas’ Xospata for NHS use

Cost-effectiveness watchdog backtracks on previous rejection

- PMLiVE

Roche pays $775m upfront to access Blueprint’s RET programme

Expands on initial deal that is worth up to $1bn

- PMLiVE

Tecentriq misses the mark in advanced ovarian cancer

PD-L1 inhibitor failed to improved progression-free survival

Roche Basel Switzerland

New data reinforces safety profile of Roche’s Hemlibra

Blockbuster haemophilia A treatment presents a strong challenge to rival drugs

Impetus Digital Fireside Chat with Jim Lefevere from Roche

Jim Lefevere from Roche, discusses the changes in digital marketing strategies, workflow, team dynamics, and required skill sets among Pharma teams brought on by COVID-19. We also touch on the slow but...

Impetus Digital

Mistura Informatics Pharmacist Donates Medicines Information Software to Tackle COVID-19

Mistura Informatics are donating their medicines information Software to the NHS for free to reduce pressure on NHS frontline staff during the COVID-19 crisis.

Onyx Health

AstraZeneca AZ

AZ’s Imfinzi gets US OK in small cell lung cancer, challenging Tecentriq

First checkpoint inhibitor to challenge Roche's Tecentriq in this indication

- PMLiVE

NHS to set up hospital in ExCeL Centre as coronavirus cases grow

Over half a million people have also volunteered with the health service

Roche Basel Switzerland

FDA approves Roche’s Actemra COVID-19 trial

Plans to initiate trial in early April

- PMLiVE

NICE looks internally for new chief executive

Deputy chief exec Gillian Leng is set to take the helm

Roche Basel Switzerland

FDA okays Roche’s COVID-19 diagnostic test

Increases capacity for testing as coronavirus cases grow

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links